Marcelo J A Amar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6748715/publications.pdf

Version: 2024-02-01

25	1,299	471509	642732
papers	citations	17 h-index	23 g-index

26	26	26	1737
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complex association of apolipoprotein Eâ€“containing HDL with coronary artery disease burden in cardiovascular disease. JCI Insight, 2022, 7, .	5.0	10
2	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. Lipids in Health and Disease, 2021, 20, 170.	3.0	6
3	LCAT protects against Lipoproteinâ€X formation in a murine model of drugâ€induced intrahepatic cholestasis. Pharmacology Research and Perspectives, 2020, 8, e00554.	2.4	7
4	Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects. Journal of Clinical Lipidology, 2020, 14, 53-65.e2.	1.5	13
5	Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults. Nutrients, 2020, 12, 749.	4.1	27
6	A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology, 2020, 5, 540.	6.1	259
7	A dual apolipoprotein C-II mimeticâ€“apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Science Translational Medicine, 2020, 12, .	12.4	56
8	Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Lowâ€Density Lipoprotein Receptorâ€Deficient Mice. Molecular Nutrition and Food Research, 2019, 63, e1900120.	3.3	33
9	Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys. Regulatory Toxicology and Pharmacology, 2018, 100, 59-67.	2.7	12
10	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1454-1457.	3.6	35
11	Randomized double blind clinical trial on the effect of oral Î±-cyclodextrin on serum lipids. Lipids in Health and Disease, 2016, 15, 115.	3.0	33
12	Human SR-BI and SR-BII Potentiate Lipopolysaccharide-Induced Inflammation and Acute Liver and Kidney Injury in Mice. Journal of Immunology, 2016, 196, 3135-3147.	0.8	50
13	A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein Eâ€“Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 227-235.	2.5	48
14	Hydrophobic Amino Acids in the Hinge Region of the 5A Apolipoprotein Mimetic Peptide are Essential for Promoting Cholesterol Efflux by the ABCA1 Transporter. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 50-58.	2.5	17
15	Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. , 2011, 130, 83-91.		53
16	Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?. Current Atherosclerosis Reports, 2011, 13, 249-256.	4.8	84
17	5A, an Apolipoprotein A-I Mimetic Peptide, Attenuates the Induction of House Dust Mite-Induced Asthma. Journal of Immunology, 2011, 186, 576-583.	0.8	68
18	5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 634-641.	2.5	103

#	Article	IF	Citations
19	Lecithin: cholesterol acyltransferase â€“ from biochemistry to role in cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 163-171.	2.3	160
20	Apoliprotein A-I Mimetic Peptide and Sickle Vasculopathy: Mouse Model Study of Acute Administration.. Blood, 2009, 114, 1521-1521.	1.4	0
21	Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides. Journal of Biological Chemistry, 2008, 283, 32273-32282.	3.4	87
22	HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Review of Cardiovascular Therapy, 2008, 6, 1203-1215.	1.5	67
23	Sickle Cell Pulmonary Hypertension and Dysregulated NO Axis in a Mouse Model Are Modulated by Apolipoprotein a-1 Availability. Blood, 2008, 112, 2499-2499.	1.4	0
24	Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Current Opinion in Investigational Drugs, 2007, 8, 201-12.	2.3	38
25	The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice. Journal of Biological Chemistry, 2004, 279, 45312-45321.	3.4	30